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INTRODUCTION

RESULTS

Previous investigations on COVID-19 vaccination indicated
ARs were mostly self-limited; however, there were a few
potentially severe reactions. Mild and self-limited reactions
studied were injection site reaction, tinnitus, and most
common flu-like symptoms (1,4). Some less frequent but
severe reactions include Guillain-Barre Syndrome, Bell’s
Palsy, and myocarditis (1,3,6). Vaccination reactions also
varied across gender, age, blood type, and previous history
of COVID-19 infection (2,5,6).
The primary objective of this survey is to determine side
effects experienced after receiving the Pfizer, Moderna, or
J&J COVID-19 vaccinations, accomplished by sending an
online survey.
Specifically, it was conducted to determine:
(1) incidence of adverse reactions (ARs) to COVID-19
vaccinations within Philadelphia Campus of PCOM;
(2) if these reactions are related to previous COVID-19
infection or underlying health conditions;
(3) how these reactions affected attitudes towards
receiving future booster immunizations

Figure 1: 68% of survey respondents identified as female, whereas 31% of participants
identified as male. This shows a slightly higher response rate from females and slightly
lower response rate from males when compared with the gender breakdown of PCOM
Philadelphia students and employees.

Figure 4: In the above figure, we compared the co-morbidity of hypertension and the adverse
effects that were experienced post COVID vaccine

This research is logical for this population because there is
a high vaccination rate among the PCOM Philadelphia
community. Information gathered is needed because of
significant public health concern regarding ARs to COVID19 vaccines and this data collection process can provide
additional information.
Potential benefits to participants and the society at large
include gaining a more informed understanding of COVID19s vaccine adverse reactions and potentially mitigating
fears of adverse reactions, which can in turn enhance
public health and social welfare through increased
vaccination rates.

METHODS

Of a total of 4,053 eligible persons, responses were
received from 758 (18.7%). Sixty-seven percent of
respondents were between 20-29 years old.
- 98.6% of respondents reported being vaccinated
against COVID-19
- 93.4% of respondents received a COVID-19 booster
- 59.6% of respondents experienced an AR to COVID19 vaccination
- No difference between different age groups and
rates of ARs
- Rate of ARs was slightly higher amongst
individuals without Hx of prior COVID infection
- No significant difference between the blood type
and ARs
- O+ blood type had the lowest rate of COVID
infection, as reported elsewhere (5)
- No correlation between hypertension and ARs.
However, a variety of ARs to the COVID vaccine
occurred if a person had a HX of hypertension

CONCLUSION

A

Figure 2: Ages Vs. Adverse Reactions from COVID Vaccinations. We compared the
rates of adverse reactions to the COVID vaccine and the ages of people who
responded to the survey. There was no significant difference in adverse reaction
rates and age

FIGURE 5: Data shows similar rates of adverse reactions to COVID vaccination in
individuals with no prior COVID infection (60%) when compared to individuals who were
infected with COVID prior to vaccination (57%).

An IRB-approved 16-question survey was created using
SurveyMonkey and distributed via email to students, faculty,
and staff at the Philadelphia campus of PCOM. Questions
included:
●
Are you vaccinated against COVID19?
●
Which vaccination did you receive and how many doses?
●
Age range, gender, race, blood type, smoking history,
and underlying health conditions.
●
History of positive COVID test prior to vaccination,
reactions to the COVID infection and/or vaccination, and
booster status.
●
Participants who indicated that they had either a
previous COVID19 infection or a reaction to the COVID19
vaccination were asked to specify which reactions were
experienced.

Our data show a slight increase among females
who took the survey compared to their proportion; for
males, it was lower. However, the rate of ARs was not
different between gender.
These data showed no important difference among
most age groups and rates of ARs or between blood
type and ARs. However, in confirmation of previous
reports, those with O+ type had the lowest frequency
of COVID infection; this did not occur with ARs. In
those without a history of prior COVID infection, the
frequency of ARs was slightly higher than those with
such exposure. There was a variety of ARs in
individuals with hypertension.
Information collected is also important to help
reduce COVID vaccine and booster hesitancy,
especially since boosters are becoming more common
as different variants of COVID emerge. Future
endeavors could include longitudinal COVID
vaccination studies comparing long term side effects
of the COVID vaccine at 1, 5 and 10 years.
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